HomeCompareLBPS vs YUM

LBPS vs YUM: Dividend Comparison 2026

LBPS yields 121.21% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LBPS wins by $8.84M in total portfolio value
10 years
LBPS
LBPS
● Live price
121.21%
Share price
$1.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.95M
Annual income
$3,410,602.48
Full LBPS calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — LBPS vs YUM

📍 LBPS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBPSYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBPS + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBPS pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBPS
Annual income on $10K today (after 15% tax)
$10,303.03/yr
After 10yr DRIP, annual income (after tax)
$2,899,012.11/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, LBPS beats the other by $2,864,635.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBPS + YUM for your $10,000?

LBPS: 50%YUM: 50%
100% YUM50/50100% LBPS
Portfolio after 10yr
$4.53M
Annual income
$1,725,523.00/yr
Blended yield
38.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

LBPS
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBPS buys
0
YUM buys
0
No recent congressional trades found for LBPS or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBPSYUM
Forward yield121.21%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$8.95M$107.9K
Annual income after 10y$3,410,602.48$40,443.52
Total dividends collected$8.14M$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: LBPS vs YUM ($10,000, DRIP)

YearLBPS PortfolioLBPS Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$22,821$12,121.21$10,982$282.06+$11.8KLBPS
2$50,271$25,852.41$12,189$438.29+$38.1KLBPS
3$107,013$53,222.70$13,731$688.32+$93.3KLBPS
4$220,388$105,884.01$15,789$1,097.12+$204.6KLBPS
5$439,612$203,797.23$18,679$1,785.08+$420.9KLBPS
6$850,309$379,924.02$22,975$2,988.18+$827.3KLBPS
7$1,596,614$686,783.92$29,784$5,200.49+$1.57MLBPS
8$2,913,579$1,205,201.50$41,408$9,539.16+$2.87MLBPS
9$5,172,959$2,055,429.68$63,071$18,765.27+$5.11MLBPS
10$8,945,669$3,410,602.48$107,930$40,443.52+$8.84MLBPS

LBPS vs YUM: Complete Analysis 2026

LBPSStock

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Full LBPS Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this LBPS vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBPS vs SCHDLBPS vs JEPILBPS vs OLBPS vs KOLBPS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.